A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
Completed · Phase 3 · NCT07117487
Conditions: Respiratory Syncytial Virus
At a glance
- Research payments reported, 2025
- $1.6M
- U.S. investigators named
- 11
- Sites paid
- 2
- Planned or actual enrollment
- 507
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1345 (biological)
- Dates
- Started 2025-08-05; completion 2026-03-27
- Results posted
- Not yet
The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
From ClinicalTrials.gov, last updated 2026-05-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $1.6M in research payments for this study in 2025 (90 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Robert A. Williams JR., M.D. Family Medicine · Ventura, CA
- Jose F. Cardona, M.D. General Practice · Miami, FL
- Paul S. Bradley, MD Internal Medicine · Savannah, GA
- Robert J. Buynak, M.D. Internal Medicine · Valparaiso, IN
- William F. Beacham, M.D. OB-GYN (Obstetrics & Gynecology) · Hammond, LA
- Shishir K. Khetan, MD Internal Medicine · Rockville, MD
- Jay R. Meyer, MD Emergency Medicine · Lincoln, NE
- P. M. Stone, MD Critical Care Medicine · Ashland, OR
- Sarah I. Smiley, D.O. Hospitalist · Austin, TX
- Michael P. Zimmerman, M.D. Emergency Medicine · Austin, TX
- Thomas A. Piscitelli, D.O. Internal Medicine · North Prince George, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Velocity Clinical Research Inc $1.1M
- Indago Research and Health $550,103
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.